ATE500819T1 - Stabilisierte pharmazeutische feste zusammensetzungen von arzneimitteln mit geringer löslichkeit, poloxameren und stabilisierenden polymeren - Google Patents

Stabilisierte pharmazeutische feste zusammensetzungen von arzneimitteln mit geringer löslichkeit, poloxameren und stabilisierenden polymeren

Info

Publication number
ATE500819T1
ATE500819T1 AT04806432T AT04806432T ATE500819T1 AT E500819 T1 ATE500819 T1 AT E500819T1 AT 04806432 T AT04806432 T AT 04806432T AT 04806432 T AT04806432 T AT 04806432T AT E500819 T1 ATE500819 T1 AT E500819T1
Authority
AT
Austria
Prior art keywords
solid compositions
poloxamers
low solubility
pharmaceutical solid
stabilizing polymers
Prior art date
Application number
AT04806432T
Other languages
English (en)
Inventor
Marshall David Crew
Ravi Mysore Shanker
Daniel Tod Smithey
Warren Kenyon Miller
Dwayne Thomas Friesen
Original Assignee
Bend Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bend Res Inc filed Critical Bend Res Inc
Application granted granted Critical
Publication of ATE500819T1 publication Critical patent/ATE500819T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT04806432T 2003-12-31 2004-12-20 Stabilisierte pharmazeutische feste zusammensetzungen von arzneimitteln mit geringer löslichkeit, poloxameren und stabilisierenden polymeren ATE500819T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53384803P 2003-12-31 2003-12-31
PCT/IB2004/004260 WO2005065656A2 (en) 2003-12-31 2004-12-20 Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers, and stabilizing polymers

Publications (1)

Publication Number Publication Date
ATE500819T1 true ATE500819T1 (de) 2011-03-15

Family

ID=34748971

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04806432T ATE500819T1 (de) 2003-12-31 2004-12-20 Stabilisierte pharmazeutische feste zusammensetzungen von arzneimitteln mit geringer löslichkeit, poloxameren und stabilisierenden polymeren

Country Status (9)

Country Link
US (1) US20070148232A1 (de)
EP (1) EP1701703B1 (de)
JP (1) JP2007517015A (de)
AT (1) ATE500819T1 (de)
BR (1) BRPI0418294A (de)
CA (1) CA2551254A1 (de)
DE (1) DE602004031767D1 (de)
MX (1) MXPA06007512A (de)
WO (1) WO2005065656A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1789020A2 (de) 2004-08-31 2007-05-30 Pfizer Products Inc. Pharmazeutische dosierformen mit einem arzneimittel mit geringer löslichkeit und einem polymer
WO2006060711A2 (en) 2004-12-03 2006-06-08 Merck & Co., Inc. Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition
WO2007060540A1 (en) * 2005-11-25 2007-05-31 Aurobindo Pharma Limited Stable dosage forms of an antidepressant
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
KR20080062430A (ko) * 2006-12-29 2008-07-03 에스케이케미칼주식회사 보관안정성이 우수한 아토르바스타틴 함유 경구투여용 제제
US9254268B2 (en) * 2007-09-25 2016-02-09 Solubest Ltd. Compositions comprising lipophilic active compounds and method for their preparation
WO2010107040A1 (ja) * 2009-03-19 2010-09-23 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗剤を含有する固形製剤
CN102458368B (zh) 2009-05-13 2014-02-26 巴斯夫欧洲公司 含有基于聚醚的共聚物与微水溶性聚合物组合的固体药物制剂
EP2477606A1 (de) * 2009-09-18 2012-07-25 Basf Se Schnell lösliche feste pharmazeutische zubereitungen enthaltend amphiphile copolymere auf basis von polyethern in kombination mit hydrophilen polymeren
PT2493312T (pt) 2009-10-26 2021-11-25 Merck Sharp & Dohme Composições farmacêuticas sólidas contendo um inibidor de integrase
EP2366378A1 (de) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Donepezilformulierungen mit verzögerter Freisetzung
US8524276B2 (en) 2010-03-11 2013-09-03 Wyeth, Llc Oral formulations and lipophilic salts of methylnaltrexone
DE102012105512A1 (de) * 2012-06-25 2014-04-24 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur verlängerten Freisetzung von Wirkstoffen
CN104721141A (zh) * 2013-12-18 2015-06-24 博瑞生物医药技术(苏州)有限公司 抗真菌药物固体分散体
CN107148265B (zh) 2014-07-02 2019-04-05 纽约州立大学研究基金会 具有高的负载物与表面活性剂比率的剥离了表面活性剂的胶束组合物
US20160200925A1 (en) * 2015-01-08 2016-07-14 Canon Kabushiki Kaisha Image recording method, ink, and liquid composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
EP1027886B1 (de) * 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmazeutische feste Dispersionen
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
SK12682001A3 (sk) * 1999-12-08 2002-07-02 Pharmacia Corporation, Corporate Patent Department Celecoxib v tuhej forme so zvýšenou biologickou dostupnosťou
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
JP5102423B2 (ja) * 2000-04-20 2012-12-19 オバン・エナジー・リミテッド 改善された水不溶性薬剤粒子の処理
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
KR20020014570A (ko) * 2000-08-18 2002-02-25 김충섭 고체분산화시킨 무정형 이프리플라본의 제조방법
BR0307332A (pt) * 2002-02-01 2004-12-07 Pfizer Prod Inc Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
RS61604A (en) * 2002-02-01 2006-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
GB2394417A (en) * 2002-10-24 2004-04-28 Novartis Ag Solid dispersion comprising a piperidine substance P antagonist and a carrier

Also Published As

Publication number Publication date
EP1701703B1 (de) 2011-03-09
JP2007517015A (ja) 2007-06-28
DE602004031767D1 (de) 2011-04-21
MXPA06007512A (es) 2006-08-31
WO2005065656A2 (en) 2005-07-21
EP1701703A2 (de) 2006-09-20
WO2005065656A3 (en) 2006-07-13
BRPI0418294A (pt) 2007-05-02
CA2551254A1 (en) 2005-07-21
US20070148232A1 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
ATE500819T1 (de) Stabilisierte pharmazeutische feste zusammensetzungen von arzneimitteln mit geringer löslichkeit, poloxameren und stabilisierenden polymeren
ES2897976T3 (es) Composiciones para implantes in situ biodegradables inyectables
DE60220049D1 (de) Pharmazeutische zusammensetzungen enthaltend eine feste dispersion eines im wasser schwerlöslichen arzneimittels und ein löslichkeitsteigerndes polymer
DE60233874D1 (de) Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
UY27641A1 (es) Composiciones farmacéuticas de dispersiones amorfas de fármacos y materiales que forman microfases lipófilas
JP2005289996A5 (de)
NO20050419L (no) Farmasoytiske blandinger av legemidler og polymerer av halv-orden
CY1109861T1 (el) Διαδερμικο θεραπευτικο συστημα για την ασθενεια του παρκινσον που προκαλει υψηλα επιπεδα πλασματος της ροτιγοτινης
EA200201254A1 (ru) Высококонцентрированные стабильные растворы мелоксикама
EA200200431A1 (ru) Фармацевтические композиции, обеспечивающие повышенные концентрации лекарства
BR0202375A (pt) Composições farmacêutica compreendendo drogas e polìmeros de aumento da concentração
NO923986D0 (no) Polymer legemiddel-utleveringsanordning
PE20040103A1 (es) Metodo y formas de dosificacion para incrementar la solubilidad de composiciones de farmaco para administracion controlada
JP2005511720A (ja) 無針注射用の安定な高濃度メロキシカム溶液
BR0113570A (pt) Cápsula rìgida
DK1256343T3 (da) Flibanserin til behandlingen af extrapyramidale bevægelseslidelser
EA200301279A1 (ru) Фармацевтические композиции адсорбатов аморфного лекарственного средства
BRPI0507683A8 (pt) dose unitária de formulação farmacêutica com liberação controlada, seu processo de preparação e uso de um copolímero de poli(acrilato de etila, metacrilato de metila) neutro
ATE427760T1 (de) Erodierbare polymere zur injektion
Patel et al. Formulation Evaluation and optimization Of stomach specific in situ gel of Ranitidine hydrochloride
DK1105102T3 (da) Injicerbart farmaceutisk præparat på basis af et farmaceutisk acceptabelt salt af clopidogrel eller ticlopidin
SE9301877D0 (sv) In situ gel for therapeutic use
DK1152763T3 (da) Anvendelse af desozypeganin til behandling af stofafhængighed
MX2021002385A (es) Composicion farmaceutica para administracion oral.
RU2002131189A (ru) Анкардин-retard-средство пролонгированного антикальциевого действия

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties